Updated just now · Live
Stock analysis, price data, and AI-powered insights for Agenus Inc (AGEN).
Agenus Inc operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for AGEN.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). AGEN Stock Intelligence Report. [stoxpulse.com/stocks/agen]
Disclaimer: The information on this page about Agenus Inc (AGEN) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Agenus Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Agenus To Present Initial Phase 2 Data For Botensi...
9h ago
Agenus to Present First Phase 2 Botensilimab Data ...
9h ago
StoxPulse AI results for AGEN: Pulse Score 58/100. Primary sentiment trends from 6 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$169.7M
P/E Ratio
—
EPS
$1.94
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Agenus To Present Initial Phase 2 Data For Botensilimab Research Across Colorectal Cancer, Melanoma, And Translational Research At American Society Of Clinical Oncology Annual Meeting May 29 - June 2
Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
Agenus reports phase II data demonstrating immune reprogramming and durable survival with botensilimab, balstilimab and agent-797 in PD-1 refractory gastroesophageal cancer
Agenus Announces Phase II Data Showing Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab And agenT-797 in PD-1 Refractory Gastroesophageal Cancer; The Study Did Not Meet Its Primary Endpoint Of ORR
Agenus : Corporate Overview